| Primary information |
|---|
| sequence ID | Seq_8357 |
| Peptide sequence | TLEIPGNSDPNMIPDGDFNSYVR |
| CancerPDF_ID | CancerPDF_ID43, CancerPDF_ID873, CancerPDF_ID1058, CancerPDF_ID1903, CancerPDF_ID1909, CancerPDF_ID3168, |
| PMID | 16896061,19795908,16395409,21136997,21136997,21136997 |
| Protein Name | Complement C4 precursor,Complement C4-A,Complement C4 precursor,Complement C4-B,Complement C4-B,Complement C4-A |
| UniprotKB Entry Name | "CO4A_HUMAN,CO4B_HUMAN",CO4A_HUMAN,CO4A_HUMAN,CO4B_HUMAN,CO4B_HUMAN,CO4A_HUMAN |
| Fluid | Serum,Plasma,Serum,Serum,Serum,Plasma |
| M/Z | 2551.06,"1276.08, 851.05",2551.06,2550.16967,2566.16458,2550.1697 |
| Charge | 1,"2, 3",1,1,1,1 |
| Mass (in Da) | 2551.16,NA,NA,NA,NA,NA |
| fdr | NA,NA,NA,NA,NA,NA |
| Profiling Technique | MALDI-TOF,LC-MS,MALDI-TOF,LC-MS,LC-MS,LC-MS |
| Peptide Identification technique | Q/TOF MS/MS,MALDI-TOF/TOF,Q/TOF/TOF and LC-MS/MS,LC-MS-MS/MS,LC-MS-MS/MS,LC-MS-MS/MS |
| Quantification Technique | NA,LC-MRM (multiple reaction monitoring),NA,LC-ESI-MS,LC-ESI-MS,LC-ESI-MS |
| Labelled/Label Free | Label Free,Labelled,Label Free,Label Free,Label Free,Label Free |
| FDR | NA,less than 7%,less than 1 “5,NA,NA,NA |
| CancerPDF_ID | CancerPDF_ID43, CancerPDF_ID873, CancerPDF_ID1058, CancerPDF_ID1903, CancerPDF_ID1909, CancerPDF_ID3168, |
| p-Value | 1.00E-05,NA,NA,NA,NA,NA |
| Software | MASCOT,FlexAnalysis 3.0 and Biotools 3.0 software,MASCOT (v 2.0.04 for Windows),MASCOT(v. 2.2.01),MASCOT(v. 2.2.01),MASCOT(v. 2.2.01) |
| Length | 23,23,23,23,23,23 |
| Cancer Type | Metastatic thyroid carcinomas,Ductal adenocarcinoma of the pancreas (DAP),"Advanced Prostate, Breast and Bladder cancer",Colorectal cancer,Colorectal cancer,Normal |
| Database | NCBI refseq Protein Database,NCBI refseq Protein Database,NCBI refseq Protein Database,SwissProt Database,SwissProt Database,SwissProt Database |
| Modification | NA,NA,NA,NA,Oxidation of Met,NA |
| Number of Patients | 40 metastatic thyroid carcinoma patients and 40 normal for training phase and 10 metastatic thyroid carcinoma and 10 normal individuals for independent validation,"42 normal, 28 patients","Advanced prostate (n = 32), breast (n = 21), and bladder (n = 20) cancer, 33 healthy in training test set, In validation set 41 independent serum samples from patients with advanced prostate cancer (prostate 2 [PR2])",30 patients and 30 healthy controls,30 patients and 30 healthy controls,27 healthy individuals |
| Regulation | NA,NA,NA,NA,NA,NA |
| Validation | Independent validation,NA,Independent validation,Leave One out Cross validation,Leave One out Cross validation,Leave One out Cross validation |
| Sensitivity | 95% on independent dataset,NA,97.5% on independent validation dataset,NA,NA,NA |
| Specificity | 95% on independent dataset,NA,NA,NA,NA,NA |
| Accuracy | NA,NA,97.5 % on validation dataset,NA,NA,NA |
| Peptide Atlas | PeptideAtlas |
| IEDB | |